Dr. Vinay Prasad, the head of the U.S. Food and Drug Administration's vaccines and biologics unit, is set to leave the agency at the end of April. His departure follows a tenure marked by significant disputes over the review of vaccines, gene therapies, and treatments for rare diseases. The FDA commissioner, Dr. Marty Makary, announced Prasad's exit, stating he would return to his position as a professor at the University of California San Francisco School of Medicine. Makary characterized Prasad's time at the FDA as a productive one-year sabbatical, during which he "accomplished much."
Prasad's division recently engaged in a notable disagreement with the Dutch drugmaker UniQure concerning the future development of its gene therapy for Huntington's disease. His work at the FDA, which began in May 2025, saw him frequently challenge the agency's established processes for approving drugs and COVID-19 vaccines. This critical stance reportedly aligned with that of Commissioner Makary, who had consistently lauded Prasad's intellect and contributions.
Read More: 5 Million Brain Tumor Patients Need Radiosurgery But Few Get It
However, Prasad also became a focal point for criticism from certain political factions. Right-wing activists, including Laura Loomer, drew attention to Prasad's prior remarks that were critical of former President Donald Trump and supportive of Senator Bernie Sanders. This scrutiny reportedly intensified in recent weeks. Sources familiar with the situation indicated to The Associated Press that Prasad's exit was prompted by a series of recent controversies. This follows a pattern where similar concerns raised by Loomer have previously preceded dismissals of national security officials under the Trump administration.